Testing for Secondary Resistance BCR-ABL Mutations
MolecularMD currently offers screening for mutations in ABL. For these tests, RNA is extracted from blood and cDNA is prepared. The cDNA is then analyzed as detailed below. |
Test Specifications
| |
Test |
| |
T315I |
ABL Kinase |
| Method |
FRET |
Direct DNA Sequencing |
| Limit of Detection |
10% of the mutant allele among non-mutated alleles
|
20-30% of the mutant allele among non-mutated alleles
|
| Specimen Requirements* |
10cc of whole blood in EDTA tube or 5cc
of whole blood in two PAXgene tubes |
10cc of whole blood in EDTA tube or 5cc
of whole blood in two PAXgene tubes |
| Reporting |
T315I mutation or no T315I mutation in BCR-ABL tyrosine kinase domain |
Amino acid change in ABL kinase domain |
| Turnaround Time |
4-5 business days * |
8-10 business days.
4-5 business days if
MolecularMD has most recent patient RNA. * |
* MolecularMD accepts Saturday deliveries
|
